T-Cell Receptor
UbiVac Showcases First ‘Dark Matter’ Cancer Immunotherapy Clinical Data at SITC 2025 Annual Meeting
UbiVac; DPV-001; cancer immunotherapy; dark matter; dark genome; alternatives neoantigens; T cell receptor (TCR); head and neck cancer; SITC 2025; clinical trial; combination therapy; anti-PD-1; immunopeptidome
Genentech to End $2B Cell Therapy Collaboration with Adaptive Biotechnologies
Genentech; Adaptive Biotechnologies; cell therapy; collaboration termination; T-cell receptor; TruTCR platform; personalized cancer therapy; $2 billion deal
FDA Approves Tecelra, the First Engineered Cell Therapy for Solid Tumors, to Treat Synovial Sarcoma
Tecelra, Adaptimmune, FDA approval, engineered cell therapy, solid tumor, synovial sarcoma, MAGE-A4 antigen, TCR cell therapy
Galapagos Partners with Adaptimmune for $665M T-Cell Therapy Collaboration
Galapagos, Adaptimmune, T-cell therapy, MAGE-A4 TCR, Uza-cel, Biobucks collaboration, Licensing deal, Financing, Next-generation therapy